The Food and Drug Administration (FDA) approved a third over-the-counter version of naloxone nasal spray on June 16, 2026. The newly approved product, Rextovy, contains 4 milligrams of naloxone and is intended for the emergency treatment of opioid overdose. Consumers will be able to purchase it directly from pharmacies, convenience stores, and online.
✓ AI-Debiased Article
4
Wire-neutral
provisional
FDA Approves Third Over-the-Counter Naloxone Nasal Spray
The FDA has approved Rextovy, a 4 milligram naloxone nasal spray, making it the third over-the-counter version available for the emergency treatment of opioid overdose. This product will be accessible for purchase in various retail locations.
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
FDA approves third over-the-counter opioid overdose nasal spray
Neutral Headline
FDA Approves Third Over-the-Counter Naloxone Nasal Spray